ANX Mast Therapeutics, Inc.

MicroStockProfit.com announces an investment report featuring ADVENTRX Pharmaceuticals Inc. (AMEX:ANX). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/ANX

ADVENTRX Pharmaceuticals Inc. (ANX) is a development-stage biopharmaceutical company. The Company's business is focused on in-licensing, developing and commercializing product candidates for the treatment of cancer. Its lead product candidates, ANX-530 and ANX-514, are emulsion formulations of marketed chemotherapy drugs. ANX is focused primarily on evaluating strategic options, including the sale or exclusive license of one or more of its product candidate programs, a strategic business merger and other similar transactions. In October 2008, ANX announced that it had discontinued active work on all product candidates other than ANX-530 and ANX-514. Its wholly owned subsidiaries include SD Pharmaceuticals, Inc. (SDP) and ANX (Europe) Ltd. 

Message Board Search for ANX: http://www.boardcentral.com/boards/ANX

In the report, the analyst notes:

"ANX's net loss applicable to common stock for the second quarter of 2010 was $5.0 million, or $0.39 per share, compared to net loss applicable to common stock of $3.8 million, or $1.02 per share, for the same period in 2009. Included in net loss applicable to common stock for the three months ended June 30, 2010, and 2009 were non-cash, deemed dividend expenses of $3.1 million and $1.2 million, respectively, related to the Company's May 2010 and June 2009 registered direct equity financings.  

"ANX recently announced that it has engaged the investment banking firm Canaccord Genuity Inc. to advise the Company and its board of directors as it seeks to expand its product candidate pipeline.  To assist in evaluating potential acquisition and merger opportunities, the ANX board of directors has formed a Special Committee, which includes Eric K. Rowinsky and Michael M. Goldberg and is chaired by Odysseas D. Kostas."

To read the entire report visit: www.microstockprofit.com/lp/ANX

See what investors are saying about ANX at http://www.stockhideout.com

Get breaking news on ANX at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT:  MicroStockProfit.com
          Brian Johnson
          1-888-307-2850
          info@microstockprofit.com